TRAVERE THERAPEUTICS for TRAVERE THERAPEUTICS
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER New | — |
| CHRISTOPHER PORTER | — |
Pharmacy PHA
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER New | — |
| CHRISTOPHER PORTER | — |
Medical/Disease Research/Clinical Labs MED
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER New | — |
| CHRISTOPHER PORTER | — |
Medicare/Medicaid MMM
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER | — |
| CHRISTOPHER PORTER | — |
Copyright/Patent/Trademark CPT
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER | — |
| CHRISTOPHER PORTER | — |
Taxation/Internal Revenue Code TAX
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSE GALLAGHER | — |
| CHRISTOPHER PORTER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.